Tofersen Early Access Program Now Open to SOD1-ALS Patients

Tofersen Early Access Program Now Open to SOD1-ALS Patients

298406

Tofersen Early Access Program Now Open to SOD1-ALS Patients

The first part of Biogen’s early access program for tofersen is now open to patients with the most rapidly progressing cases of familial amyotrophic lateral sclerosis (ALS), the company announced. These patients, with familial ALS caused by mutations in the SOD1 gene, will be the first to receive the experimental therapy, which aims to slow disease progression. The program’s first part is meant for people with very rapidly progressing SOD1-associated familial ALS — defined as a…

You must be logged in to read/download the full post.